Anti-obesity Pharmacotherapy and Inflammation

Part of paid clinical trials in New Orleans, Louisiana.

Sponsor
Louisiana State University Health Sciences Center in New Orleans
Study ID
NCT05756764
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Medication for weight loss
  • Phentermine-Topiramate combination — DRUG
    Medication for weight loss
  • Phentermine — DRUG
    Medication for weight loss
  • Tirzepatide — DRUG
    Medication for weight loss
  • Topiramate — DRUG
    Medication for weight loss
  • Diethylpropion — DRUG
    Medication for weight loss
  • Naltrexone/Bupropion — DRUG
    Medication for weight loss
  • Liraglutide — DRUG
    Medication for weight loss

Study Details

This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

Key Dates

Start date
Jun 1, 2023
Status verified
Sep 2025
Primary completion
Jan 30, 2026
Completion
Feb 20, 2026

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Patients with obesity on pharmacotherapy
    Before initiation of pharmacotherapy (as part of the standard-of-care treatment) and 6 months after initiated medication

Primary Outcome Measure

weight loss [ Time Frame: baseline and 24 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NONew OrleansLouisiana70112-
Ochsner Health System - BiospecimenNew OrleansLouisiana70121-

Find similar trials in New Orleans, LA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO· New Orleans, LAOchsner Health System - Biospecimen· New Orleans, LA

Related Studies